Authors
Mohammad Masoudi, Negin Ahangarian, Hossein Ammarlou
Published in
Molecular biology research communications. Volume 15. Issue 3. Pages 159-164.
Abstract
Pancreatic cancer remains one of the most lethal malignancies worldwide due to late diagnosis and limited therapeutic response. Gemcitabine is widely used as a first-line chemotherapeutic agent, and SH3D21 has been identified as a gemcitabine sensitizer in pancreatic cancer cells. Here, we investigated whether rs34416442 polymorphism of SH3D21 is associated with overall survival in a cohort of Iranian patients with pancreatic cancer. Peripheral blood samples were collected from 26 patients, and genotyping was performed. Patients were followed and survival outcomes were analyzed using Kaplan-Meier curves and the log-rank test. Three genotypes-TTT/TTT, TTT/T, and T/T-were identified with frequencies of 38%, 54%, and 8%, respectively. Significant differences in survival were observed among genotypes (p = 0.004). Patients carrying the T/T genotype exhibited markedly shorter mean overall survival (135 days) compared with those harboring at least one TTT allele (395 and 450 days). A recessive model further confirmed the reduced survival associated with the homozygous T/T genotype (p = 0.001). Stratified analyses showed that this association persisted in both gemcitabine-received (p = 0.006) and not-received (p = 0.016) subgroups. While different genotype-based survival patterns were observed among patients of the two groups. The TTT/T genotype showed the best survival in patients receiving gemcitabine, while TTT/TTT genotype did so in patients not receiving gemcitabine. These findings suggest SH3D21 rs34416442 as a potential predictive biomarker for pancreatic cancer.
PMID:
42459940
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0